Wnt/IL‐1β/IL‐8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5

@article{Miloevi2019WntIL1IL8AC,
  title={Wnt/IL‐1$\beta$/IL‐8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5},
  author={Vladan D. Milo{\vs}evi{\'c} and Joanna Kopecka and Iris Chiara Salaroglio and Roberta Libener and Francesca Napoli and Stefania Izzo and Sara Orecchia and Preeta Ananthanarayanan and Paolo Bironzo and Federica Grosso and Fabrizio Tabb{\`o} and Valentina Comunanza and Teodora Alexa-Stratulat and Federico Bussolino and Luisella Righi and Silvia Novello and Giorgio Vittorio Scagliotti and Chiara Riganti},
  journal={International Journal of Cancer},
  year={2019},
  volume={146}
}
Malignant pleural mesothelioma (MPM) is a tumor with high chemoresistance and poor prognosis. MPM‐initiating cells (ICs) are known to be drug resistant, but it is unknown if and how stemness‐related pathways determine chemoresistance. Moreover, there are no predictive markers of IC‐associated chemoresistance. Aim of this work is to clarify if and by which mechanisms the chemoresistant phenotype of MPM IC was due to specific stemness‐related pathways. We generated MPM IC from primary MPM samples… 
Blocking the autocrine regulatory loop of Gankyrin/STAT3/CCL24/CCR3 impairs the progression and pazopanib resistance of clear cell renal cell carcinoma
TLDR
Targeting the gankyrin/STAT3/CCL24/CCR3 autocrine-regulatory loop may serve as a remedy for patients with advanced clear-cell renal cell carcinoma, and combining ganksyrin and STAT3 or CCL24 expression with the current clinical indicators better predicts ccRCC patient prognosis.
Transcriptomic alterations
Malignant pleural mesothelioma (MPM) is a universally lethal type of cancer that is increasing in incidence worldwide; therefore, the development of new drugs for MPM is an urgent task. Bullfrog
Drug resistance and Cancer stem cells
TLDR
CSCs are a subset of tumor cells that are capable of self-renewal and multilineage progenitor expansion that are known to be intrinsically resistant to anticancer treatments and are the major source of therapy resistance.
HDAC1 regulates the chemosensitivity of laryngeal carcinoma cells via modulation of interleukin-8 expression.
TLDR
The HDAC1/IL-8 axis can confer chemotherapeutic resistance to LSCC cells and this study reveals that 5-FU and CDDP treatment increase the expression of histone deacetylase 1 (HDAC1) in LS CC cells.
Human drug efflux transporter ABCC5 confers acquired resistance to pemetrexed in breast cancer
TLDR
It is indicated that ABCC5 expression was associated with pemetrexed resistance in vitro and in vivo, and it may serve as a target or biomarker for the optimization of pemberrexed regimen in breast cancer treatment.
Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression.
TLDR
Pre-clinical data demonstrate that targeting IL-8 or its receptors enables improved tumor killing by immune cells, and treatment strategies combining blockade of the IL-7/IL-8R axis with ICI ultimately improve anti-tumor efficacy.
Emetine Synergizes with Cisplatin to Enhance Anti-Cancer Efficacy against Lung Cancer Cells
TLDR
It is suggested that emetine could suppress the growth of NSCLC cells through the Wnt/β-catenin pathway and contribute to a synergistic effect in combination with cisplatin.
Impact of ABC Transporters in Osteosarcoma and Ewing’s Sarcoma: Which Are Involved in Chemoresistance and Which Are Not?
TLDR
This review provides an overview of ABC transporters, both related and unrelated to MDR, which have been studied in osteosarcoma and Ewing’s sarcoma to provide a more complete overview of the biological impacts of these molecules in these neoplasms.
Hypoxia, endoplasmic reticulum stress and chemoresistance: dangerous liaisons
TLDR
It is suggested that pharmacological inhibitors of HIF-1α and modulators of ER stress, although characterized by low specificty and anti-cancer efficacy when used as single agents, may be repurposed as chemosensitizers against hypoxic and chemorefractory tumors in the next future.
Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies
TLDR
An overview on the most relevant emerging drug resistance-related biomarkers, therapeutic targets and new agents or novel candidate treatment strategies, which have emerged in HGOS are highlighted and suggested for HGOS to improve the success rate of clinical trials.
...
1
2
...

References

SHOWING 1-10 OF 51 REFERENCES
Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation
TLDR
Increased expression of macrophage colony-stimulating-factor-1-receptor (M-CSF/CSF-1R) mRNA in mesothelioma versus normal tissue specimens is reported and it is demonstrated that CSF- 1R expression identifies chemoresistant cells of mesothelial nature in both primary cultures and mesotHelioma cell lines.
Putative cancer stem cells may be the key target to inhibit cancer cell repopulation between the intervals of chemoradiation in murine mesothelioma
TLDR
Putative MSC possess the property of stemness showing more resistance to chemoradiation, suggesting that MSC may play critical roles in cancer cell repopulation.
SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells
TLDR
It is shown that pemetrexed-treated mesothelioma cells undergo accelerated senescence, characterized by the secretion of proinflammatory and mitogenic cytokines, reminiscent of an SASP (senescence-associated secretory phenotype), and that small hairpin RNA-mediated ablation of STAT3 deeply attenuates the induction of EMT genes and the increase of ALDHbright cells induced by SASP-cytokines.
Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma.
TLDR
The association of proteasome and lysosome inhibitors reverses cisplatin resistance by restoring LIP levels and may represent a new adjuvant strategy in MPM treatment.
Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed.
TLDR
Evidence of putative CSCs conferring drug-resistance to cisplatin and pemetrexed in MPM cell lines is provided and specific targeting of these drug-resistant cells, while considering the functional heterogeneity of the MPM subtypes, may contribute to more focused and effective chemotherapeutic regimens for malignant pleural mesothelioma.
The c-MYC-ABCB5 axis plays a pivotal role in 5-fluorouracil resistance in human colon cancer cells
TLDR
It is found that the c‐MYC expression level in primary colorectal cancer tissues correlated with the recurrence rate following 5‐fluorouracil (5‐FU)‐based adjuvant chemotherapy, and that c‐ MYC confers resistance to 5‐FU through regulating ABCB5 expression in human colon cancer cells.
Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDHhighCD44+ phenotype and sphere-forming capacity
TLDR
This study shows that ALDHhigh CD44+ cells are implicated in conveying tolerance to cisplatin in the three MPM cell lines, and widens the window for identification and targeting of a drug-resistant population which may improve the current treatment modalities in mesothelioma.
Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy.
TLDR
The PI3K pathway is playing an important role in regulating the SP phenotype in MPM cells and inhibition of this activity may contribute to a more efficient cancer treatment.
Wnt2 as a new therapeutic target in malignant pleural mesothelioma
TLDR
It is proposed that inhibition of Wnt2 is of therapeutic interest in the development of more effective treatments for MPM and the effects of the anti‐Wnt2 antibody and of Alimta on MPM cell proliferation.
Simultaneous overactivation of Wnt/β-catenin and TGFβ signalling by miR-128-3p confers chemoresistance-associated metastasis in NSCLC
TLDR
It is reported that high levels of microRNA-128-3p is key to concomitant development of Chemoresistance and metastasis in residual NSCLC cells having survived repeated chemotherapy and correlates with chemoresistance, aggressiveness and poor prognosis inNSCLC patients.
...
1
2
3
4
5
...